CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10–30 mg orally once daily (starting dose 10 mg, titrated over 12 weeks)AI-extracted
Key inclusion· 3
  • ✓Diagnosis of current Major Depressive Disorder
  • ✓Age 18–65 years
  • ✓Medication-free for ≥1 week before study start
Key exclusion· 7
  • ✕Active suicidality
  • ✕Pregnant or breastfeeding
  • ✕Serious or unstable medical illness (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, hematologic)
  • ✕History of seizure disorder or hypothyroidism

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00464711
NCT00464711Phase 4Completed
CompareCT.gov

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Massachusetts General Hospital·interventional·Posted Apr 24, 2007·Updated Jan 4, 2017

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Major Depressive Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
CollaboratorsMclean Hospital

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 24, 2007
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.2 years ago

Interventions

Escitalopramdrug

Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.